The global vaccine contract manufacturing market size accounted for USD 4.24 billion in 2024, grew to USD 4.72 billion in 2025 and is projected to surpass around USD 12.26 billion by 2034, representing a healthy CAGR of 11.20% between 2024 and 2034. The North America vaccine contract manufacturing market size is calculated at USD 1.78 billion in 2024 and is expected to grow at a fastest CAGR of 11.21% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Vaccine Contract Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Vaccine Contract Manufacturing Market, by Vaccine Type, 2024-2034
8.1.1 Attenuated
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Inactivated
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Subunit-based
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Toxoid-based
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. DNA-based
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Vaccine Contract Manufacturing Market, by Workflow, 2024-2034
9.1.1. Downstream
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Upstream
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Electrolyte
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Separator
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Vaccine Contract Manufacturing Market, by Application, 2024-2034
10.1.1. Human Use
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Veterinary
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.1.3. Market Revenue and Forecast, by Application (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.2.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.3.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Vaccine Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Workflow (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1. Lonza
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Ajinomoto Althea, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck KgaA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cytovance Biologics
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Catalent, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. IDT Biologika GmbH
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Albany Molecular Research, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. PRA Health Sciences
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. ICON plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample